Table 1 Baseline characteristics of COVID-19 patients by dexamethasone treatment
Variable | All | No dexamethasone | Dexamethasone | P** | |||
|---|---|---|---|---|---|---|---|
n | n | n | |||||
Age in years, median [IQR] | 89 | 63.0 [53.0–72.0] | 17 | 56.0 [46.5–69.5] | 72 | 63.0 [54.3–72.8] | 0.128 |
Male, % | 89 | 41.6 | 17 | 29.4 | 72 | 44.4 | 0.258 |
Smoking history, % | 75 | 46.7 | 15 | 46.7 | 60 | 46.7 | 1.000 |
BMI, median [IQR], kg/m2 | 55 | 30.3 [26.6–34.5] | 13 | 26.6 [23.0–32.7] | 42 | 31.2 [28.4–35.4] | 0.057 |
sRAGE, median [IQR], pg/mL | 89 | 2852 [1487–5235] | 17 | 1486 [1068–2125] | 72 | 3431 [1709–5989] | 0.002 |
CRP, median [IQR], pg/mL | 78 | 72.0 [35.3–156.0] | 15 | 14.0 [5.0–49.0] | 63 | 90.0 [47.0–202.0] | < 0.001 |
IL-6, median [IQR], pg/mL | 89 | 21.8 [7.9–55.3] | 17 | 9.5 [4.4–24.7] | 72 | 23.7 [8.7–60.5] | 0.025 |
DDimer, median [IQR], ng/mL | 85 | 816 [512–1644] | 15 | 678 [567–1119] | 70 | 895 [501–1722] | 0.223 |
eGFR, median [IQR], mL/min/1.73m2 | 84 | 69.5 [60.0–88.5] | 17 | 78.0 [68.0–110.0] | 67 | 68.0 [59.0–86.0] | 0.060 |
Diabetes, % | 89 | 22.5 | 17 | 11.8 | 72 | 25.0 | 0.240 |
Hypercholesterolemia, % | 89 | 5.9 | 17 | 5.9 | 72 | 5.6 | 0.985 |
Hypertension, % | 89 | 29.2 | 17 | 5.9 | 72 | 34.7 | 0.019 |
Cardiovascular disease*, % | 89 | 10.1 | 17 | 17.6 | 72 | 8.3 | 0.252 |
DVT or PE, % | 89 | 3.4 | 17 | 0.0 | 72 | 4.2 | 0.392 |
COPD, % | 89 | 10.1 | 17 | 5.9 | 72 | 11.1 | 0.520 |
Cancer, % | 89 | 12.4 | 17 | 5.9 | 72 | 13.9 | 0.367 |
NEWS2, median [IQR] | 89 | 5.0 [3.0–6.0] | 17 | 3.0 [0.0–5.0] | 72 | 5.0 [3.3–7.0] | 0.004 |
Remdesivir, % | 89 | 37.1 | 17 | 0.0 | 72 | 45.8 | < 0.001 |
Admitted to ICU, % | 89 | 9.0 | 17 | 0.0 | 72 | 11.1 | 0.150 |
Days in hospital, median [IQR] | 89 | 7.0 [3.0–13.0] | 17 | 0.0 [0.0–9.0] | 72 | 7.5 [4.0–13.8] | 0.001 |